BRAIN Biotech AG (LON:0RFI)
London
· Delayed Price · Currency is GBP · Price in EUR 2.830
+0.020 (0.71%)
At close: Feb 21, 2025
BRAIN Biotech AG Income Statement
Financials in millions EUR. Fiscal year is October - September.
Millions EUR. Fiscal year is Oct - Sep.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | 2019 - 2015 |
| Revenue | 55.5 | 56.23 | 50.3 | 39.22 | 39.06 | Upgrade
|
| Revenue Growth (YoY) | -1.29% | 11.79% | 28.23% | 0.40% | -2.45% | Upgrade
|
| Cost of Revenue | 24.94 | 25.8 | 22.69 | 17.4 | 17.46 | Upgrade
|
| Gross Profit | 30.56 | 30.42 | 27.61 | 21.82 | 21.61 | Upgrade
|
| Selling, General & Admin | 26.36 | 23.34 | 23.06 | 20.5 | 19.26 | Upgrade
|
| Other Operating Expenses | 8.39 | 7.99 | 6.59 | 4.69 | 5.18 | Upgrade
|
| Operating Expenses | 39.58 | 35.98 | 33.99 | 29.21 | 28.38 | Upgrade
|
| Operating Income | -9.01 | -5.56 | -6.38 | -7.39 | -6.78 | Upgrade
|
| Interest Expense | -1.94 | -0.86 | -0.53 | -0.52 | -0.67 | Upgrade
|
| Interest & Investment Income | - | - | 0 | 0.01 | 0.01 | Upgrade
|
| Earnings From Equity Investments | -0.5 | -1.49 | -2.43 | -1.72 | -2.39 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.11 | -0.06 | 0.12 | -0.04 | -0.06 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.52 | 0.09 | 0.28 | 3.98 | 0.82 | Upgrade
|
| EBT Excluding Unusual Items | -11.04 | -7.89 | -8.93 | -5.68 | -9.06 | Upgrade
|
| Merger & Restructuring Charges | - | -0.28 | -0.48 | -0.31 | -1.09 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -0.01 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 0.54 | 2.36 | 0.58 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 0.65 | - | - | Upgrade
|
| Asset Writedown | - | - | - | - | -0.41 | Upgrade
|
| Other Unusual Items | 0.05 | 0.13 | 0.24 | 1.14 | 0.63 | Upgrade
|
| Pretax Income | -10.99 | -7.49 | -6.17 | -4.28 | -9.94 | Upgrade
|
| Income Tax Expense | 0.11 | 0.63 | 0.18 | 0.4 | -0.93 | Upgrade
|
| Earnings From Continuing Operations | -11.1 | -8.11 | -6.34 | -4.68 | -9.02 | Upgrade
|
| Minority Interest in Earnings | -0.03 | -0.17 | -0.25 | -0.29 | -0.67 | Upgrade
|
| Net Income | -11.13 | -8.28 | -6.59 | -4.97 | -9.68 | Upgrade
|
| Net Income to Common | -11.13 | -8.28 | -6.59 | -4.97 | -9.68 | Upgrade
|
| Shares Outstanding (Basic) | 22 | 22 | 22 | 20 | 19 | Upgrade
|
| Shares Outstanding (Diluted) | 22 | 22 | 22 | 20 | 19 | Upgrade
|
| Shares Change (YoY) | - | - | 9.55% | 6.89% | 3.33% | Upgrade
|
| EPS (Basic) | -0.51 | -0.38 | -0.30 | -0.25 | -0.52 | Upgrade
|
| EPS (Diluted) | -0.51 | -0.38 | -0.30 | -0.25 | -0.52 | Upgrade
|
| Free Cash Flow | -5.14 | -6.84 | -7.29 | -5.16 | -7.59 | Upgrade
|
| Free Cash Flow Per Share | -0.24 | -0.31 | -0.33 | -0.26 | -0.41 | Upgrade
|
| Gross Margin | 55.07% | 54.11% | 54.89% | 55.63% | 55.31% | Upgrade
|
| Operating Margin | -16.24% | -9.89% | -12.69% | -18.84% | -17.35% | Upgrade
|
| Profit Margin | -20.05% | -14.72% | -13.10% | -12.68% | -24.79% | Upgrade
|
| Free Cash Flow Margin | -9.25% | -12.16% | -14.48% | -13.15% | -19.42% | Upgrade
|
| EBITDA | -5.73 | -2.39 | -3.27 | -4.1 | -3.7 | Upgrade
|
| EBITDA Margin | -10.32% | -4.25% | -6.51% | -10.45% | -9.48% | Upgrade
|
| D&A For EBITDA | 3.29 | 3.18 | 3.11 | 3.29 | 3.07 | Upgrade
|
| EBIT | -9.01 | -5.56 | -6.38 | -7.39 | -6.78 | Upgrade
|
| EBIT Margin | -16.24% | -9.89% | -12.69% | -18.84% | -17.35% | Upgrade
|
| Revenue as Reported | 55.52 | 57.14 | 53.07 | 40.73 | 39.24 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.